DanCann Pharma A/S: Highly promising analysis results
COPENHAGEN, Denmark, 19 January 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the ambitions to enter the European market with inhouse-produced biomaterial during 2022 has been further supported by the in-house analysis results that the Company has obtained after testing the selected cannabis genetics.DanCann Pharma has now reduced the number of varieties from 95 to nine. The Tetrahydrocannabinol (THC) content of these genetics are in all cases above the general minimum requirements from the market –